- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06507787
Valutazione dell'impatto dell'esame del sangue EDIT-B® sullo stato di salute dei pazienti che presentano un episodio depressivo maggiore. Utilità clinica e aspetti medico-economici (SEM EDIT-B)
Depression is one of the most common mental disorders, affecting nearly 10% of men and 20% of women worldwide. It is associated with a significant increase in mortality, mainly due to suicidal behavior. The Diagnostic and Statistical Manual of Mental Disorders (DSM) defines a Major Depressive Episode (MDE) by a combination of at least five different symptoms, with at least one depressed mood or loss of interest. MDEs can occur in isolation or as part of Major Depressive Disorder (MDD) or bipolar disorder (BD). Bipolar disorders affect 2% of the world's population and are defined by episodes of mania (Type I BD) or hypomania (Type II BD) alternating with episodes of depression and periods of remission.
Depression occurring whether in the context of BD or MDD is defined with the same clinical criteria. However, the pharmacological treatments are different in the two groups. In particular, antidepressants prescribed without a thymoregulator in bipolar patients can lead to a worsening of the episode, favoring suicidal behavior or a manic turn.
The average interval between the onset of BD symptoms and appropriate diagnosis is estimated to be approximately 7 years, which delays appropriate management and treatment and increases the risk of suicide.
Biological markers able to differentiate between the different types of depression were lacking before the advent of EDIT-B®; one of the main objectives of this research is to measure the clinical impact of the use of EDIT-B® in the short and medium term on the management of patients with BD and major depression. The health economic aspect will also be considered.
In total, 450 patients in two different groups (EDIT-B® group and control group) will be recruited over a study timeline of 24 months. Study participation is over 6 months with 4 visits.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Benjamin Dubuc
- Email: benjamin.dubuc@alcediag-alcen.com
Backup dei contatti dello studio
- Nome: Mary Menhem, PharmD, MSc
- Numero di telefono: +33788970700
- Email: mary.menhem@alcediag-alcen.com
Luoghi di studio
-
-
-
Erstein, Francia
- Non ancora reclutamento
- CH Erstein
-
Contatto:
- Geraldine Pfleger, Dr
- Numero di telefono: +33 3 90 64 21 46
- Email: geraldine.pfleger@ch-erstein.fr
-
Investigatore principale:
- Geraldine Pfleger, Dr
-
Issy-les-Moulineaux, Francia
- Non ancora reclutamento
- AP-HP Corentin Celton
-
Contatto:
- Nicolas Hoertel, Pr
- Numero di telefono: +33 1 58 00 44 21
- Email: nicolas.hoertel@aphp.fr
-
Investigatore principale:
- Nicolas Hoertel, Pr
-
La Roche-sur-Foron, Francia
- Non ancora reclutamento
- Etablissement Public de Santé Mentale (EPSM) 74
-
Contatto:
- Rocco De Filippis, Pr
- Numero di telefono: +33 749121443
- Email: defilippis-r@ch-epsm74.fr
-
Investigatore principale:
- Rocco De Filippis, Pr
-
Lyon, Francia
- Reclutamento
- Clinique Villa des Roses
-
Contatto:
- Pascal Frilloux, Dr
- Numero di telefono: +33 4 78 15 00 00
- Email: pascal.frilloux-ext@inicea.fr
-
Investigatore principale:
- Pascal Frilloux, Dr
-
Montrond-les-Bains, Francia
- Reclutamento
- Clinique Le Clos Montaigne
-
Contatto:
- Christophe Aimo, Dr
- Numero di telefono: +33 4 77 36 01 00
- Email: christophe.aimo@inicea.fr
-
Investigatore principale:
- Christophe Aimo, Dr
-
Paris, Francia
- Reclutamento
- GHU Paris Psychiatrie et Neurosciences
-
Contatto:
- Juan Zambrano
- Numero di telefono: +33145658153
- Email: juan.zambrano@ghu-paris.fr
-
Investigatore principale:
- Chantal Henry, Pr
-
Ville-d'Avray, Francia
- Non ancora reclutamento
- Clinique Médicale de Ville d'Avray
-
Contatto:
- Jérôme Dischamps
- Numero di telefono: +33147094314
- Email: jdischamps@wanadoo.fr
-
Investigatore principale:
- Jérôme Dischamps
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Patients with a MDE, moderate to severe (DSM V criteria and MADRS score ≥19)
-
Age between 18 and 65 years, gender indifferent
-
Benefitting from health insurance coverage
-
Having signed an informed consent and agreed to follow the study protocol to completion
-
Patients for whom there is doubt regarding a bipolar disorder diagnosis, and/or presenting one or more of the following criteria:
- More than 3 episodes of MDE in personal medical history
- Psychotic symptoms
- Family history of bipolar disorder
- Onset of the first MDE before the age of 25
- Atypical symptoms or mixed features during depressive episodes
- Addiction
- Personal history of suicide attempts
- Resistance to antidepressants
- Postpartum depression within 6 months of birth
Exclusion Criteria:
- Depression in the context of schizophrenia or autism spectrum disorder
- Patient with a well-established diagnosis of bipolar disorder
- Patients who is already receiving a mood stabilizer
- Severe somatic diseases that may interfere with the follow-up or associated with treatments at risk of secondary manic decompensation
- Neurodegenerative diseases
- Pregnant women
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: With EDIT-B test result
The investigator will have the EDIT-B® test result to guide the treatment strategy. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
|
Comparatore placebo: Without EDIT-B test result
The investigator will not have the EDIT-B® test result, but EDIT-B® is still performed on participants in the beginning of the study. |
EDIT-B® is the first blood test for the differential diagnosis of bipolar disorder (BD) and major depression. It consists of a biological analysis (including targeted RNA sequencing) followed by a software interpretation thanks to an algorithm developed with AI. The test is CE marked, clinically validated on two independent cohorts and shows an excellent performance with a sensitivity and specificity of more than 80%. For performing the test, a blood sample of 2.5 ml will be drawn using PAXgene™ Blood RNA tubes (Becton Dickinson, UK) according to the manufacturer's instructions. THE RESULT OF THE TEST WILL NOT BE GIVEN TO THE PARTICIPANT BEFORE THE END OF THE STUDY. The objective of EDIT-B® is to reduce the time to diagnosis of BD, which is currently 7 years on average. This will improve the patient pathway, thanks to faster access to appropriate care - whether for unipolar or bipolar patients - with a major medical, social and financial impact. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Improvement in depressive symptoms between inclusion and 15-16 weeks visit.
Lasso di tempo: 4 months (from inclusion visit to 15-16 weeks visit)
|
Clinically meaningful improvement at week 15-16 in depressive symptoms, defined as a 6-point or greater reduction in MADRS total score from baseline, without a manic switch, defined as an increase in the YMRS total score above 11 from baseline, measured using a composite endpoint. |
4 months (from inclusion visit to 15-16 weeks visit)
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SEM EDIT-B
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .